Global Chronic Renal Failure Therapeutics Market 2019-2023

慢性腎不全治療法の世界市場:降圧治療法、抗貧血治療、その他

◆タイトル:Global Chronic Renal Failure Therapeutics Market 2019-2023
◆商品コード:IRTNTR31343
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2019年6月19日
◆ページ数:145
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア太平洋、ヨーロッパ、中東・アフリカ、北米、南米
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥262,500見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥315,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、慢性腎不全治療法の世界市場について調べ、慢性腎不全治療法の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、慢性腎不全治療法の市場規模をセグメンテーション別(製品別(降圧治療法、抗貧血治療、その他))と地域別(グローバル、アジア太平洋、ヨーロッパ、中東・アフリカ、北米、南米)に分けて算出しました。
・サマリー
・レポートの範囲
・慢性腎不全治療法の市場状況
・慢性腎不全治療法の市場規模
・慢性腎不全治療法の市場予測
・慢性腎不全治療法の世界環境:ファイブフォース分析
・市場セグメンテーション:製品別(降圧治療法、抗貧血治療、その他)
・慢性腎不全治療法の顧客状況
・主要地域別市場規模:グローバル、アジア太平洋、ヨーロッパ、中東・アフリカ、北米、南米
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...

Global Chronic Renal Failure Therapeutics Market: About this market

Chronic renal failure is a general term for a set of heterogeneous disorders that affect the structure and function of the kidney. Technavio’s chronic renal failure therapeutics market analysis considers sales of antihypertensive therapeutics, antianemia therapeutics, and others. Our analysis also considers the sales of chronic renal failure therapeutics in Asia, Europe, North America, and ROW. In 2018, the antihypertensive therapeutics segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the inclusion of antihypertensive therapeutics into various reimbursement schemes will play a significant role in the antihypertensive therapeutics segment to maintain its market position. Also, our global chronic renal failure therapeutics market report looks at factors such as the rising prevalence of chronic renal failure, a strong pipeline and recent approvals, and initiatives from government agencies. However, high genericization of the market, lack of disease-modifying agents, and late diagnosis of polypharmacy may hamper the growth of the chronic renal failure therapeutics industry over the forecast period.

Global Chronic Renal Failure Therapeutics Market: Overview

Rising prevalence of chronic renal failure

The rise in the number of people suffering from cardiovascular and metabolic disorders can result in an increased prevalence of chronic renal failure. There is a high concentration of patients with chronic renal failure from the US, Europe, and Asia. This will boost the need for chronic renal failure therapeutics in these countries and lead to the expansion of the global chronic renal failure therapeutics market at a CAGR of almost 5% during the forecast period.

Development of novel hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors

It has been observed that the oral administration of HIF-PH drugs is ideal for patients. Also, oral HIF-PH inhibitors exhibit minimal side-effects in comparison to other therapeutics. The penetration of these drugs across healthcare centers of various countries is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global chronic renal failure therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global chronic renal failure therapeutics market is fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading chronic renal failure therapeutics manufacturers, that include Amgen Inc., AstraZeneca Plc, Bayer AG, F. Hoffmann-La Roche Ltd., and Pfizer Inc.

Also, the chronic renal failure therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【資料の目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

Market segmentation by product

Comparison by product

Antihypertensive therapeutics – Market size and forecast 2018-2023

Antianemia therapeutics – Market size and forecast 2018-2023

Others – Market size and forecast 2018-2023

Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Development of novel hypoxia-inducible factor prolyl hydroxylase

(HIF-PH) inhibitors

Exploring research toward precision medicine

Strategic alliances

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Amgen Inc.

AstraZeneca Plc

Bayer AG

F. Hoffmann-La Roche Ltd.

Pfizer Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global pharmaceuticals market

Exhibit 02: Segments of global pharmaceuticals market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Product – Market share 2018-2023 (%)

Exhibit 18: Comparison of product

Exhibit 19: Antihypertensive therapeutics – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: Antihypertensive therapeutics – Year-over-year growth 2019-2023 (%)

Exhibit 21: Antianemia therapeutics – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Antianemia therapeutics – Year-over-year growth 2019-2023 (%)

Exhibit 23: Others – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: Others – Year-over-year growth 2019-2023 (%)

Exhibit 25: Market opportunity by product

Exhibit 26: Customer landscape

Exhibit 27: Market share by geography 2018-2023 (%)

Exhibit 28: Geographic comparison

Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 30: North America – Year-over-year growth 2019-2023 (%)

Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 33: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 35: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 36: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 37: Key leading countries

Exhibit 38: Market opportunity

Exhibit 39: Late Stage Molecules for the treatment of chronic renal failure

Exhibit 40: Impact of drivers and challenges

Exhibit 41: HIF-PH inhibitors under Phase III development

Exhibit 42: Strategic alliances

Exhibit 43: Vendor landscape

Exhibit 44: Landscape disruption

Exhibit 45: Vendors covered

Exhibit 46: Vendor classification

Exhibit 47: Market positioning of vendors

Exhibit 48: Amgen Inc. – Vendor overview

Exhibit 49: Amgen Inc. – Business segments

Exhibit 50: Amgen Inc. – Organizational developments

Exhibit 51: Amgen Inc. – Geographic focus

Exhibit 52: Amgen Inc. – Key offerings

Exhibit 53: AstraZeneca Plc – Vendor overview

Exhibit 54: AstraZeneca Plc – Business segments

Exhibit 55: AstraZeneca Plc – Organizational developments

Exhibit 56: AstraZeneca Plc – Geographic focus

Exhibit 57: AstraZeneca Plc – Key offerings

Exhibit 58: Bayer AG – Vendor overview

Exhibit 59: Bayer AG – Business segments

Exhibit 60: Bayer AG – Organizational developments

Exhibit 61: Bayer AG – Geographic focus

Exhibit 62: Bayer AG – Segment focus

Exhibit 63: Bayer AG – Key offerings

Exhibit 64: F. Hoffmann-La Roche Ltd. – Vendor overview

Exhibit 65: F. Hoffmann-La Roche Ltd. – Business segments

Exhibit 66: F. Hoffmann-La Roche Ltd. – Organizational developments

Exhibit 67: F. Hoffmann-La Roche Ltd. – Geographic focus

Exhibit 68: F. Hoffmann-La Roche Ltd. – Segment focus

Exhibit 69: F. Hoffmann-La Roche Ltd. – Key offerings

Exhibit 70: Pfizer Inc. – Vendor overview

Exhibit 71: Pfizer Inc. – Business segments

Exhibit 72: Pfizer Inc. – Organizational developments

Exhibit 73: Pfizer Inc. – Geographic focus

Exhibit 74: Pfizer Inc. – Segment focus

Exhibit 75: Pfizer Inc. – Key offerings

Exhibit 76: Validation techniques employed for market sizing

Exhibit 77: Definition of market positioning of vendors



【掲載企業】

Amgen Inc.、AstraZeneca Plc、Bayer AG、F. Hoffmann-La Roche Ltd.、Pfizer Inc.

【免責事項】
※当資料上の情報/データは調査会社が信頼できると判断した情報源から入手したものに基づき作成しましたが、その正確性・完全性を保証するものではありません。当資料に記載された情報/データ/見解/仮説などは作成時点又は発行時点における調査会社の判断であり、その後の状況変化に応じて変更される場合があります。当資料上の情報/データに基づいたお客様の意思決定又は実行による結果について、調査会社/発行会社/販売会社H&Iグローバルリサーチはその責を負いかねますのでご了承ください。英文資料の紹介ページにおける日本語題名/概要/目次はH&Iグローバルリサーチが翻訳した内容であり、翻訳の正確性・完全性を保証するものではありません。

[慢性腎不全治療法の世界市場:降圧治療法、抗貧血治療、その他]についてメールでお問い合わせはこちら


◆H&Iグローバルリサーチ株式会社のお客様(例)◆